Binimetinib vs Trametinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MEK1/2 · full Non-Small Cell Lung Cancer pipeline

Binimetinib

Marketed by Pfizer and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT03915951 · Phase 2 · completed

This was a single-group, open-label study of 98 participants receiving encorafenib plus binimetinib, without randomization or a placebo or active-control arm. The primary imaging-based tumor-response endpoint was reported descriptively, so there was no controlled statistical comparison demonstrating that binimetinib improved outcomes.

Next expected readout: August 2027 · NCT05355701 (registry estimate)

No aligned efficacy figure on record for this race.

Trametinib

Marketed by Novartis and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01362296 · Phase 2 · completed

This was a randomized, active-controlled trial against a standard chemotherapy comparator, but it was conducted without blinding, and the primary progression-free-survival endpoint was not statistically different between arms (hazard ratio 1.14, 95% CI 0.75 to 1.75, p=0.5197).

Next expected readout: July 2027 · NCT03333343 (registry estimate)

Reported efficacy

Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20 (not_applicable)

Result source: NCT01336634

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBinimetinibTrametinib
PFS, median—Not reported2.7 vs 2.6vs Docetaxel2 mg · n 86NCT01362296
5 other results
  • 10.2 DAB 150MG BID, TRA 2mG QD · n 48 · Phase 2 · secondary NCT01336634
  • 10.8 DAB 150MG BID, TRA 2mG QD · n 28 · Phase 2 · secondary NCT01336634
  • 5.4 n 65 · Phase 2 · secondary NCT01336634
  • 11 DAB 150MG BID, TRA 2mG QD · n 18 · Phase 2 · secondary NCT01336634
  • 13.9 n 40 · Phase 2 · secondary NCT04452877
OS, median—Not reported8.1 vs 9.9vs Docetaxel2 mg · n 86NCT01362296
4 other results
  • 18.2 DAB 150MG BID, TRA 2mG QD · n 49 · Phase 2 · secondary NCT01336634
  • 17.3 DAB 150MG BID, TRA 2mG QD · n 27 · Phase 2 · secondary NCT01336634
  • 12.7 n 67 · Phase 2 · secondary NCT01336634
  • 25.3 n 40 · Phase 2 · secondary NCT04452877
ORR74.6%bn 59NCT03915951
3 other results
—Not reported
Duration of response, median—Not reported1.6 vs 2.9vs Docetaxel2 mg · n 10NCT01362296
5 other results
  • 9.8 DAB 150MG BID, TRA 2mG QD · n 39 · Phase 2 · secondary NCT01336634
  • 10.2 DAB 150MG BID, TRA 2mG QD · n 23 · Phase 2 · secondary NCT01336634
  • 11.8 n 27 · Phase 2 · secondary NCT01336634
  • 14.9 n 31 · Phase 2 · secondary NCT04452877
  • 13.4 DAB 150MG BID, TRA 2mG QD · n 4 · Phase 2 · secondary NCT01336634

PFS, median

Binimetinib
—Not reported
Trametinib
2.7 vs 2.6vs Docetaxel2 mg · n 86NCT01362296
5 other results
  • 10.2 DAB 150MG BID, TRA 2mG QD · n 48 · Phase 2 · secondary NCT01336634
  • 10.8 DAB 150MG BID, TRA 2mG QD · n 28 · Phase 2 · secondary NCT01336634
  • 5.4 n 65 · Phase 2 · secondary NCT01336634
  • 11 DAB 150MG BID, TRA 2mG QD · n 18 · Phase 2 · secondary NCT01336634
  • 13.9 n 40 · Phase 2 · secondary NCT04452877

OS, median

Binimetinib
—Not reported
Trametinib
8.1 vs 9.9vs Docetaxel2 mg · n 86NCT01362296
4 other results
  • 18.2 DAB 150MG BID, TRA 2mG QD · n 49 · Phase 2 · secondary NCT01336634
  • 17.3 DAB 150MG BID, TRA 2mG QD · n 27 · Phase 2 · secondary NCT01336634
  • 12.7 n 67 · Phase 2 · secondary NCT01336634
  • 25.3 n 40 · Phase 2 · secondary NCT04452877

ORR

Binimetinib
74.6%bn 59NCT03915951
3 other results
Trametinib
—Not reported

Duration of response, median

Binimetinib
—Not reported
Trametinib
1.6 vs 2.9vs Docetaxel2 mg · n 10NCT01362296
5 other results
  • 9.8 DAB 150MG BID, TRA 2mG QD · n 39 · Phase 2 · secondary NCT01336634
  • 10.2 DAB 150MG BID, TRA 2mG QD · n 23 · Phase 2 · secondary NCT01336634
  • 11.8 n 27 · Phase 2 · secondary NCT01336634
  • 14.9 n 31 · Phase 2 · secondary NCT04452877
  • 13.4 DAB 150MG BID, TRA 2mG QD · n 4 · Phase 2 · secondary NCT01336634
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Binimetinib: 3 of 4 rows · Trametinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBinimetinibTrametinib
Dropout rate
n/a: no completion milestonePreviously Treated
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
n/a: no completion milestoneTreatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
—2 mga
NCT01362296 · Phase 2
show 8 more results
n/a: no completion milestone2 mg
NCT01362296 · Phase 2
16.7%150mg BID
NCT01336634 · Phase 2 · monotherapy
14%DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
25%DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
—DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
77.5%Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
—Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
—Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
15.4%Previously Treated
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
20.3%Treatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
—2 mga
NCT01362296 · Phase 2
show 8 more results
23%2 mg
NCT01362296 · Phase 2
—150mg BID
NCT01336634 · Phase 2 · monotherapy
—DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
—DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
—DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
12.5%Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
—Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
—Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
43.6%Previously Treated
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
42.4%Treatment-Naive
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
52.2%2 mga
NCT01362296 · Phase 2
show 8 more results
36.8%2 mg
NCT01362296 · Phase 2
44%150mg BID
NCT01336634 · Phase 2 · monotherapy
66.7%DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
66.7%DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
45%DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
—Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
50%Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
6.3%Dabrafenib in Combination With Tra
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
diarrhoea 51.3%
nausea 48.7%
fatigue 41%
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
nausea 62.7%
diarrhoea 49.2%
fatigue 49.2%
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
2 mga
diarrhoea 47.8%
oedema peripheral 30.4%
rash 30.4%
NCT01362296 · Phase 2
show 7 more results
2 mg
rash 57.5%
diarrhoea 50.6%
hypertension 34.5%
NCT01362296 · Phase 2
150mg BID
pyrexia 36.9%
cough 32.1%
dry skin 31%
NCT01336634 · Phase 2 · monotherapy
DAB 150MG BID, TRA 2mG QD
pyrexia 43.9%
nausea 42.1%
vomiting 42.1%
NCT01336634 · Phase 2 · combination
DAB 150MG BID, TRA 2mG QD
pyrexia 61.1%
nausea 58.3%
diarrhoea 41.7%
NCT01336634 · Phase 2 · combination
DAB 150MG BID, TRA 2mG QD
nausea 45%
pyrexia 45%
arthralgia 40%
NCT01336634 · Phase 2 · combination
anaemia 52.5%
hypoalbuminaemia 47.5%
pyrexia 45%
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
hypoalbuminaemia 6.3%
abdominal discomfort 0%
abdominal pain upper 0%
NCT04452877 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Binimetinib

ORR 74.6% (n=59)
responder rate · % of participants
No placebo or comparator arm
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 3 more results
46.2% (n=39)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
62.7% (n=59)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
41% (n=39)
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Disease Control 64.4% (n=59) @ 24wk
responder rate · % of participants
No placebo or comparator arm
DCR After 24 Weeks by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
41% (n=39) @ 24wk
DCR After 24 Weeks by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
Time to Response 1.86 months
time to event · months
No placebo or comparator arm
TTR by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2
show 1 more result
1.74 months
TTR by IRR
NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2

Trametinib

PFS 2.7 vs 2.63 Docetaxel months2 mg
time to event · months
NCT01362296 · Phase 2 · converted to months from 11.7 weeks as posted
Duration of Response 1.55 vs 2.86 Docetaxel months2 mg
time to event · months
NCT01362296 · Phase 2 · converted to months from 6.7 weeks as posted
Overall Survival 8.1 vs 9.9 Docetaxel months2 mg
time to event · months
NCT01362296 · Phase 2
ORR 68.4% (n=57)DAB 150MG BID, TRA 2mG QD
event count · % of participants
No placebo or comparator arm
NCT01336634 · Phase 2 · combination · converted to % from 39 Participants as posted
show 3 more results
63.9% (n=36)*DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination · converted to % from 23 Participants as posted
20% (n=20)*DAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination · converted to % from 4 Participants as posted
34.6% (n=78)*
NCT01336634 · Phase 2 · monotherapy · converted to % from 27 Participants as posted
PFS 10.2 monthsDAB 150MG BID, TRA 2mG QD
time to event · months
No placebo or comparator arm
NCT01336634 · Phase 2 · combination
show 4 more results
10.8 monthsDAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
11 monthsDAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
5.4 months
NCT01336634 · Phase 2 · monotherapy
13.9 months
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 9.8 monthsDAB 150MG BID, TRA 2mG QD
time to event · months
No placebo or comparator arm
NCT01336634 · Phase 2 · combination
show 4 more results
10.2 monthsDAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
13.4 monthsDAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
11.8 months
NCT01336634 · Phase 2 · monotherapy
14.9 months
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 18.2 monthsDAB 150MG BID, TRA 2mG QD
time to event · months
No placebo or comparator arm
NCT01336634 · Phase 2 · combination
show 3 more results
17.3 monthsDAB 150MG BID, TRA 2mG QD
NCT01336634 · Phase 2 · combination
12.7 months
NCT01336634 · Phase 2 · monotherapy
25.3 months
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
ORR 75% (n=40)
absolute value · percentage points
No placebo or comparator arm
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
77.5% (n=40)
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
EQ-5D-5L VAS 1.09 score @ 12wk
absolute change · score
No placebo or comparator arm
Visual Analog Scale (VAS) - Change from BL @ Week 12
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
EQ-5D-5L VAS -1.33 score @ 12wk
absolute change · score
No placebo or comparator arm
Visual Analog Scale (VAS) - Change from BL @ End of Treatment (EOT) Disposition
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS 0.18 score @ 12wk
absolute change · score
No placebo or comparator arm
Global Health Status - Change from BL @ Week 12
NCT04452877 · Phase 2 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS -0.06 score @ 12wk
absolute change · score
No placebo or comparator arm
Global Health Status - Change from BL @ End of Treatment (EOT) Disposition
NCT04452877 · Phase 2 · registry result, not featured evidence · combination

+ 4 further endpoints in the CSV export.

Melanoma

Shared mechanism: MEK1/2 · full Melanoma pipeline

Binimetinib

Marketed by Pfizer and partners

Approved in Melanomasmall molecule
Partial signal

NCT01763164 · Phase 3 · completed

The randomized, active-controlled trial compared binimetinib with dacarbazine in 402 participants, using progression-free survival assessed by RECIST as its primary clinical endpoint. Progression-free survival favored binimetinib (p<0.001), but the open-label design limits the strength of the evidence.

Next expected readout: January 2027 · NCT03947385 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71) (met)

Result source: NCT01763164

Trametinib

Marketed by Novartis and partners

Approved in Melanomasmall molecule
Weak signal

NCT02039947 · Phase 2 · completed

The study was open-label, nonrandomized, and had no comparator arm; all participants received dabrafenib plus trametinib. Although the primary intracranial response result was reported as 45 of 76 participants (59%), the uncontrolled design provides weak evidence for trametinib’s treatment effect.

Next expected readout: February 2027 · NCT04417621 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Melanoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Trametinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Binimetinib
Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71) NCT01763164 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Binimetinib's landscape · Trametinib's landscape